Lineage Cell Therapeutics (LCTX) Amortization of Deferred Charges (2011 - 2014)
Lineage Cell Therapeutics (LCTX) reported Amortization of Deferred Charges of -$720.0 for Q4 2014, up 99.91% on a YoY basis from -$360.16 in Q4 2013, and down 157.14% quarter-over-quarter from -$280.0 in Q1 2014.
Lineage Cell Therapeutics (LCTX) Amortization of Deferred Charges (2011 - 2014) Analysis & Trends
Lineage Cell Therapeutics has reported Amortization of Deferred Charges for 4 years, with the latest figure at -$720.0 in Q4 2014.
- For the quarter ending Q4 2014, Amortization of Deferred Charges rose 99.91% year-over-year to -$720.0; the trailing twelve-month figure through Mar 2015 stood at -$720.0 (up 99.92% YoY), and the FY2023 full-year result was $22000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q4 2014 stood at -$720.0, down from -$280.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $112708.0 in Q4 2012, with the low at -$790118.0 in Q4 2013.
- Historically, Amortization of Deferred Charges has averaged -$87387.7 across 4 years, with a median of -$37898.0 in 2012.
- Annual changes were most pronounced in 2012 — Amortization of Deferred Charges jumped 331.21% — and 2013, when it tumbled 801.03%.
- Lineage Cell Therapeutics' Amortization of Deferred Charges stood at -$48746.0 in 2011, then soared by 331.21% to $112708.0 in 2012, then plunged by 801.03% to -$790118.0 in 2013, then surged by 99.91% to -$720.0 in 2014.
- The last three Amortization of Deferred Charges figures came in at -$720.0 (Q4 2014), -$280.0 (Q1 2014), and -$790118.0 (Q4 2013), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -720.00 |
| Dec 31, 2014 | -720.00 |
| Mar 31, 2014 | -280.00 |
| Mar 31, 2014 | -280.00 |
| Dec 31, 2013 | -790,118.00 |
| Dec 31, 2013 | -790,118.00 |
| Sep 30, 2013 | -48,968.00 |
| Sep 30, 2013 | -48,968.00 |
| Jun 30, 2013 | -32,918.00 |
| Jun 30, 2013 | -32,918.00 |
| Mar 31, 2013 | -42,996.00 |
| Mar 31, 2013 | -42,996.00 |
| Dec 31, 2012 | 112,708.00 |
| Dec 31, 2012 | 112,708.00 |
| Sep 30, 2012 | -36,912.00 |
| Sep 30, 2012 | -36,912.00 |
| Jun 30, 2012 | -37,105.00 |
| Jun 30, 2012 | -37,105.00 |
| Mar 31, 2012 | -38,691.00 |
| Mar 31, 2012 | -38,691.00 |